MPO and inflammatory bowel disease: Herein, we demonstrate that orally available AZD3241 (a selective, irreversible MPO inhibitor) significantly ameliorates clinical manifestations of experimental IBD through inhibiting biochemical markers of colon damage typically raised during acute inflammation in this IBD model.